A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues

• Published in: Frontiers in immunology Vol. 15; p. 1297542
• Main Authors: Huang, Yi, Liao, Chengxiao, Shen, Zefeng, Zou, Yitong, Xie, Weibin, Gan, Qinghua, Yao, Yuhui, Zheng, JunJiong, Kong, Jianqiu
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 19-02-2024
• Subjects: Bibliometrics; bladder cancer; Humans; immune checkpoint inhibitors; Immunology; Immunotherapy; Medical Oncology; neoadjuvant chemotherapy; Neoadjuvant Therapy; platin-based; Urinary Bladder Neoplasms - drug therapy; neoadjuvant chemotherapy; immune checkpoint inhibitors; platin-based; bibliometrics; bladder cancer
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1297542

Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) remains the cornerstone of treatment for muscle-invasive bladder cancer (MIBC). While platinum-based regimens have demonstrated benefits in tumor downstaging and improved long-term survival for selected patients, they may pose risks for those who are ineligible or unresponsive to chemotherapy.
We undertook a bibliometric analysis to elucidate the breadth of literature on NAC in bladder cancer, discern research trajectories, and underscore emerging avenues of investigation.
A systematic search of the Web of Science Core Collection (WoSCC) was conducted to identify articles pertaining to NAC in bladder cancer from 1999 to 2022. Advanced bibliometric tools, such as VOSviewer, CiteSpace, and SCImago Graphica, facilitated the examination and depicted the publication trends, geographic contributions, institutional affiliations, journal prominence, author collaborations, and salient keywords, emphasizing the top 25 citation bursts.
Our analysis included 1836 publications spanning 1999 to 2022, indicating a growing trend in both annual publications and citations related to NAC in bladder cancer. The United States emerged as the predominant contributor in terms of publications, citations, and international collaborations. The University of Texas was the leading institution in publication output. "Urologic Oncology Seminars and Original Investigations" was the primary publishing journal, while "European Urology" boasted the highest impact factor. Shariat, Shahrokh F., and Grossman, H.B., were identified as the most prolific and co-cited authors, respectively. Keyword analysis revealed both frequency of occurrence and citation bursts, highlighting areas of concentrated study. Notably, the integration of immunochemotherapy is projected to experience substantial growth in forthcoming research.
Our bibliometric assessment provides a panoramic view of the research milieu surrounding neoadjuvant chemotherapy for bladder cancer, encapsulating the present state, evolving trends, and potential future directions, with a particular emphasis on the promise of immunochemotherapy.